- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01300299
STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO) (STEREO)
STEREOtactic Radiation and Adjuvant Chemotherapy in Lung Cancer (STEREO)
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
This study evaluates the effect of adjuvant chemotherapy in patients who received treatment with stereotactic radiation for early stage lung cancer and who are at high risk for microscopic metastatic disease.
Chemotherapy in the form of cisplatin/docetaxel or cisplatin/pemetrexed will be administered approximately six weeks after Stereotactic Body Radiation Therapy (SBRT). Patients will then undergo follow up clinical evaluation and imaging to evaluate treatment response and for surveillance.
A patient population of 65 patients will be required. Enrollment in this protocol is planned by multi center involvement in the state of Kentucky as part of the Kentucky Trial Network (KTN).
Tipo de estudo
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40202
- James Graham Brown Cancer Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Histologically diagnosed non-small cell lung cancer(NSCLC, cT1-T3 (<= 5cm) (AJCC 7ed). The following histologies are eligible: squamous cell carcinoma, adenocarcinoma, large cell carcinoma, large cell neuroendocrine, or non-small cell carcinoma not otherwise specified; bronchioloalveolar cell carcinoma is a subtype of NSCLC but will be excluded from this study because assessment of multifocal disease spread through the airways is difficult.
- Required CT of the chest and abdomen with contrast unless medically contraindicated (evaluating both lungs, mediastinum, liver, and adrenals) and Whole Body Positron Emission Tomography (PET) for staging. An integrated PET/Computed Tomography (CT) will meet the CT and PET requirements for staging. Images must be read by a trained radiologist and performed 8 weeks prior to initiation of treatment. PET imaging must allow adequate visualization of the primary tumor, draining lymphatics in hilar and mediastinum, adrenals, and skeleton.
Note: Per Radiation Therapy Oncology Group (RTOG) 0915 inclusion criteria, patients with hilar or mediastinal lymph nodes ≤ 1cm and no abnormal hilar or mediastinal uptake on PET will be considered N0. Patients with > 1 cm hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but non-diagnostic uptake) may still be eligible if directed tissue biopsy of all abnormally identified areas are negative for cancer.
- Deemed medically inoperable by an experienced thoracic cancer clinician for a standard lobectomy and lymph node sampling/dissection. Inoperability may be defined utilizing a number of criteria. These include any of the following:
- Pretreatment Forced Expiratory Volume (FEV1) < 40% predicted
- Postoperative FEV1 < 30% predicted
- Severely reduced diffusion capacity
- Baseline hypoxemia and/or hypercapnia
- Exercise oxygen consumption < 50% predicted
- Severe pulmonary hypertension
- Diabetes mellitus with severe end organ damage
- Severe cerebral, cardiac, or peripheral vascular disease
- Decline surgery after evaluation by a thoracic surgeon
Required laboratory values within 2 weeks of chemotherapy initiation
- Absolute neutrophil count (ANC) ≥ 1500 mm3
- Platelets ≥ 100,000/mm3
- Total Bilirubin ≤ 1.5 mg/dL
- Serum glutamic oxaloacetic transaminase (SGOT)- aspartate aminotransferase (AST) < 5 x upper limit of normal (ULN}
- Serum glutamic pyruvic transaminase (SGPT)- alanine transaminase(ALT) < 5 x upper limit of normal (ULN)
- Serum Creatinine ≤ 1.5 x institutional upper limit of normal (ULN)
- For patients assigned to pemetrexed/Cisplatin therapy calculated Creatinine Clearance (CrCl) must be obtained within 2 weeks of randomization and calculated CrCl must be > 45mL/min using the standard Cockcroft and Gault formula
Exclusion Criteria:
- Primary lesion size not within the acceptable criteria
- Evidence of regional metastases or distant metastases following appropriate staging
- Previous radiation to the chest
- Chemotherapy within the previous five years
- Previous surgery for this particular lung tumor
- Plans for concomitant chemotherapy with radiation
- Active systemic or pulmonary infection
- Pregnant or lactating females
- Synchronous primary malignancy or prior malignancy in the past 2 years except for invasive malignancy that has been treated definitively and the patient remains disease free for > 3 years with life expectancy > 3 years. Previous skin cancers and carcinoma in situ treated definitively are acceptable.
- Patients assigned to pemetrexed/cisplatin therapy must NOT have squamous cell histology
- Bronchioloalveolar cell carcinoma is excluded because assessment of multifocal disease spread through the airways is difficult
- Receipt of any other investigational agents or participation in any other investigational drug study within 4 weeks preceding initiation of study treatment
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: All subjects
Subjects will receive chemotherapy after stereotactic body radiation therapy.
|
12 Gray (Gy) x 4 fractions (48 Gy) will be delivered to peripherally located tumors (> 2 cm in all directions around the proximal bronchial tree and centrally located tumors (within <2 centimeters (cm) of proximal bronchial tree).
Treatment should be given on consecutive days.
There will be 4 or 5 treatments.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
To measure the feasibility of adjuvant chemotherapy after stereotactic body radiation therapy for early stage non-small cell lung cancer (NSCLC)
Prazo: 3 years after subject enrollment
|
3 years after subject enrollment
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
---|---|
Survival rate, specifically disease-free survival (DFS) and overall survival (OS), measured by follow-up visits and tests
Prazo: 3 years after subject enrollment
|
3 years after subject enrollment
|
safety of adjuvant chemotherapy after stereotactic body radiation therapy for early stage non-small cell lung cancer (NSCLC) measured by adverse events
Prazo: 3 years after subject enrollment
|
3 years after subject enrollment
|
quality of life (QOL) measured by subject questionnaires
Prazo: 3 years after subject enrollment
|
3 years after subject enrollment
|
Measurement of biological and clinical markers for toxicity, DFS, and OS
Prazo: 3 years after subject enrollment
|
3 years after subject enrollment
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Goetz H Kloecker, MD, James Graham Brown Cancer Center
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- BCC-LUN-10-STEREO
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Stereotactic Body Radiation Therapy
-
Ottawa Hospital Research InstituteRescindidoCarcinoma Pancreático Não RessecávelCanadá